Last updated on February 2020

A Randomized Double-Blind Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine


Brief description of study

Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine

Detailed Study Description

The EMERGE trial is a multi-center, single-dose, randomized, double-blind, placebo-controlled, parallel group study in subjects with acute migraine (ages 18 to 65 years).

Clinical Study Identifier: NCT03901482

Find a site near you

Start Over

Medvadis Research Group

Watertown, MA United States
0.39miles
  Connect »

Boston Clinical Trials

Boston, MA United States
6.7miles
  Connect »